Comprehensive Cancer Center Program at Fox Chase

项目总结/摘要-总体 福克斯大通癌症中心（FCCC），现在在其第51年作为一个国家癌症研究所指定的综合癌症 自上次CCSG赠款审查以来，该中心经历了深刻的变革。2012年，福克斯 大通进入附属与坦普尔大学卫生系统，创造了一个独特的新模式， 结合了独立癌症中心的灵活性和大学的科学和临床广度， 矩阵中心。除了这一组织变化，2013年，FCCC在新的领导下， 理查德一世的任命Fisher博士担任FCCC总裁兼首席执行官和癌症中心主任。作为 由于这些发展，癌症中心的规模和范围大大扩大，无论是在 它的科学事业以及所服务的病人的数量和多样性。专注于癌症，Temple 教师已经完全融入气候变化框架公约，增加了54个新的CCSG成员，其中包括三个 领导职位（Jean-Pierre Issa，医学博士，癌症表观遗传学联合项目负责人; Susan Fisher，博士，人口科学副主任; Grace Ma，博士，社区基础主任 研究）。除了扩大成员外，这种联系还使人们能够在 天普大学，包括费尔斯癌症研究和分子生物学研究所， 以及新成立的公共卫生学院。重要的是，随着加入，FCCC现在 极大地提高了对寺庙周围集水区内服务不足人口的访问 北费城大学健康科学中心。上一笔赠款中的其他重要成就 周期包括：a）招聘Wafik El-Deiry，MD，PhD担任新的翻译副主任 加强基础研究成果的临床转化的研究; B）直接成本增加40%， 从2013年到2015年，FCCC资助的研究（2770万美元到3870万美元）; c）CCSG的43倍投资回报- （d）增加应计治疗干预性试验，从2011年的358项增加到2014年的668项 (an e）建立癌症表观遗传学前沿研究方案; f） 2011-2015年期间，通过方案内和方案间的有力合作，发表了2 200多篇论文， 其中影响因子> 8的期刊占20%，影响因子> 10的期刊占11%。这些 积极的事态发展表明了气候变化框架公约的新力量及其在照顾 这个地区的癌症患者。

PROJECT SUMMARY/ABSTRACT – OVERALL The Fox Chase Cancer Center (FCCC), now in its 51st year as an NCI-designated Comprehensive Cancer Center, has undergone a profound transformation since the time of the last CCSG grant review. In 2012, Fox Chase entered into an affiliation with the Temple University Health System, creating a unique new model that combines the flexibility of a free-standing cancer center with the scientific and clinical breadth of a university- based matrix center. In addition to this organizational change, in 2013, FCCC came under new leadership with the appointment of Richard I. Fisher, MD as President and CEO of FCCC and Cancer Center Director. As a result of these developments, the size and scope of the Cancer Center have greatly expanded, both in terms of its scientific enterprise and also in the number and diversity of the patients served. Cancer-focused, Temple faculty members have been thoroughly integrated into FCCC, adding 54 new CCSG members, including three in leadership positions (Jean-Pierre Issa, MD, PhD, Co-Program Leader for Cancer Epigenetics; Susan Fisher, PhD, Associate Director for Population Science; Grace Ma, PhD, Director of Community Based Research). In addition to expanding membership, the affiliation has enabled access to specialized expertise at Temple University, including the Fels Institute for Cancer Research and Molecular Biology, the Moulder Center for Drug Discovery, and the newly created School of Public Health. Importantly, with the affiliation, FCCC now has greatly enhanced access to an underserved population within its catchment area, surrounding the Temple University Health Science Center in North Philadelphia. Other important accomplishments within the last grant cycle include: a) Recruitment of Wafik El-Deiry, MD, PhD to a new Deputy Directorship for Translational Research to enhance the clinical translation of basic research findings; b) A 40% increase in the direct costs of funded research at FCCC from 2013 - 2015 ($27.7M to $38.7M); c) 43-fold return on investment from CCSG- supported pilot projects; d) Increased accrual to treatment interventional trials, from 358 in 2011 to 668 in 2014 (an 87% increase); e) Establishment of a cutting-edge Research Program in Cancer Epigenetics; and f) Publication of more than 2,200 papers from 2011-2015, with strong intra- and inter-programmatic collaboration, including 20% in journals with Impact Factors > 8, and 11% in journals with Impact Factors > 10. These positive developments demonstrate the renewed strength of FCCC and the importance of its role in the care of cancer patients in this region.